抗EGFRvⅢ CAR-T疗法联合Notch1通路抑制剂对人胶质瘤起始细胞自我更新能力的抑制作用OACSTPCD
Inhibitory effect of anti-EGFRv Ⅲ CAR-T lymphocytes combined with DAPT on self-renewal ability of human glioma initiating cells
目的 观察抗表皮生长因子受体vⅢ嵌合抗原受体基因修饰T淋巴细胞(抗EGFRvⅢ CAR-T)疗法联合Notch1通路抑制剂DAPT对人胶质瘤起始细胞(GICs)自我更新能力的抑制作用.方法 将胶质母细胞瘤原代细胞分为DT007和DT008两部分,经干细胞成球培养后采用免疫磁珠法分选,Western blotting法及免疫荧光法鉴定为GICs,分别命名为PA37S和PA38S.取PA37S、PA38S两种细胞,每种细胞随机分为对照组(加入细胞培养液)、DAPT组(加入10 μmol/L DAPT)、CAR-T组(加入慢病毒转染获得的抑制EGFRvⅢ表达的抗EGFRvⅢ CAR-T淋巴细胞)、CAR-T+DAPT组(加入抗EGFRvⅢ CAR-T淋巴细胞和10 μmol/L DAPT),均培养24 h.采用Western blotting法检测细胞EGFRvⅢ、Notch1活化相关指标Hes1蛋白相对表达量,成球实验检测细胞球直径和数目,极限稀释实验检测5、10、20、50、100、200、500个/孔细胞密度下的细胞球数目.结果 在PA37S、PA38S细胞中,CAR-T组、CAR-T+DAPT组EGFRvⅢ蛋白相对表达量均低于对照组、DAPT组,DAPT组、CAR-T+DAPT组Hes1蛋白相对表达量均低于对照组、CAR-T组(P均<0.05).成球实验结果显示,在PA37S、PA38S细胞中,DAPT组、CAR-T组、CAR-T+DAPT组细胞球数量和直径均低于对照组,以CAR-T+DAPT组降低更明显(P均<0.05).极限稀释实验结果显示,在PA37S细胞和PA38S细胞中,5、10个/孔细胞密度下各组细胞球数量比较差异均无统计学意义(P均>0.05);20个/孔细胞密度下CAR-T+DAPT组细胞球数量低于对照组,50、100、200个/孔细胞密度下CAR-T+DAPT组细胞球数量均低于对照组、DAPT组、CAR-T组,500个/孔细胞密度下DAPT组、CAR-T组、CAR-T+DAPT组细胞球数量均低于对照组且CAR-T+DAPT组降低更明显(P均<0.05).结论 抗EGFRvⅢ CAR-T疗法联合DAPT可抑制GICs的自我更新能力.
Objective To observe the inhibitory effect of anti-epidermal growth factor receptor vⅢ chimeric antigen receptor gene-modified T lymphocytes(anti-EGFRvⅢ CAR-T lymphocytes)combined with Notch1 pathway specific inhib-itor DAPT on the self-renewal ability of human glioma initiating cells(GICs).Methods The primary glioblastoma(GBM)cells were divided into two parts,including DT007 and DT008.After culturing stem cells into spheroids,they were sorted using immunomagnetic bead method,were identified as GICs by Western blotting and immunofluorescence,and were named PA37S and PA38S,respectively.These two types of cells were randomly divided into the control group(added with cell culture medium),DAPT group(added with 10 μ mol/L DAPT),CAR-T group(added with anti-EGFRvⅢ CAR-T lymphocytes obtained by lentivirus transfection that inhibit EGFRvⅢ expression),and CAR-T+DAPT group(added with anti-EGFRvⅢ CAR-T lymphocytes and 10 μ mol/L DAPT),respectively;all cells from the above groups were cultured for 24 h.Western blotting was used to detect the relative expression levels of EGFRvⅢ and Hes1 proteins in cells.The diameter and number of cell spheres were measured by spheroid formation experiment,and the number of cell spheres was measured by extreme dilution assay at cell densities of 5,10,20,50,100,200,and 500/well.Results In PA37S and PA38S cells,the relative expression levels of EGFRvⅢ protein in the CAR-T group and CAR-T+DAPT group were lower than those in the control group and DAPT group;the relative expression levels of Hes1 protein in the DAPT group and CAR-T+DAPT group were lower than those in the control group and CAR-T group(all P<0.05).The results of the spheroid formation experiment showed that in PA37S and PA38S cells,the number and diameter of cell spheroids in the DAPT group,CAR-T group,and CAR-T+DAPT group were lower than those in the control group,with the CAR-T+DAPT group showing a more significant decrease(all P<0.05).The results of the extreme dilution experiment showed that there was no statistically significant difference in the number of cell spheres between the 5/well and 10/well cell densities in PA37S and PA38S cells(P>0.05).At a cell density of 20/well,the number of cell spheres in the CAR-T+DAPT group was smaller than that in the control group.At the cell densities of 50/well,100/well,and 200/well,the number of cell spheres in the CAR-T+DAPT group was smaller than that in the control group,DAPT group,and CAR-T group.At a cell density of 500/well,the number of cell spheres in the DAPT group,CAR-T group,and CAR-T+DAPT group was smaller than that in the control group,and the CAR-T+DAPT group showed a more significant decrease(all P<0.05).Conclusion The combination of anti-EGFRvⅢ CAR-T lymphocytes and DAPT can inhibit the self-renewal ability of GICs.
周星辰;王大巍;赵彪;束汉生;程哲;闵敬亮
蚌埠医科大学第二附属医院神经外科,安徽 蚌埠 233000
临床医学
人胶质瘤起始细胞表皮生长因子受体vⅢ抗原受体基因修饰T淋巴细胞Notch1自我更新
glioma initiating cellsepidermal growth factor receptor vⅢchimeric antigen receptor-modified T lym-phocytesNotch1self-renewal ability
《山东医药》 2024 (035)
16-20 / 5
安徽省高校自然科学研究重点项目(2023AH052015);蚌埠医学院自然科学研究重点项目(2022byzd080).
评论